Mangoceuticals (NASDAQ:MGRX – Get Free Report) and Protara Therapeutics (NASDAQ:TARA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.
Valuation & Earnings
This table compares Mangoceuticals and Protara Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mangoceuticals | $460,000.00 | 13.81 | -$20.64 million | ($1.49) | -0.25 |
| Protara Therapeutics | N/A | N/A | -$57.44 million | ($1.34) | -2.85 |
Insider and Institutional Ownership
56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Mangoceuticals has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.
Profitability
This table compares Mangoceuticals and Protara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -4,639.13% | -112.00% | -104.96% |
| Protara Therapeutics | N/A | -38.70% | -36.02% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Mangoceuticals and Protara Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Protara Therapeutics | 1 | 0 | 7 | 0 | 2.75 |
Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 587.17%. Given Protara Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Mangoceuticals.
Summary
Protara Therapeutics beats Mangoceuticals on 7 of the 13 factors compared between the two stocks.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
About Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
